Grape King Bio Ltd
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics… Read more
Grape King Bio Ltd (1707) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.014x
Based on the latest financial reports, Grape King Bio Ltd (1707) has a cash flow conversion efficiency ratio of 0.014x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$161.09 Million) by net assets (NT$11.64 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Grape King Bio Ltd - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Grape King Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Grape King Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Grape King Bio Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Opko Health Inc
NASDAQ:OPK
|
-0.027x |
|
Energy Vault Holdings Inc
NYSE:NRGV
|
-0.145x |
|
REGULUS THER.COMPAR DL001
F:7RG0
|
N/A |
|
Ucap Cloud Information Technology Co Ltd
SHG:688228
|
0.015x |
|
PT Sarana Menara
JK:TOWR
|
0.152x |
|
Logility Supply Chain Solutions, Inc.
NASDAQ:LGTY
|
-0.052x |
|
Sihui Fuji Electronics Technology Co Ltd
SHE:300852
|
0.032x |
|
Chongqing Genrix Biopharmaceutical Co. Ltd. A
SHG:688443
|
N/A |
Annual Cash Flow Conversion Efficiency for Grape King Bio Ltd (2002–2024)
The table below shows the annual cash flow conversion efficiency of Grape King Bio Ltd from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$11.79 Billion | NT$1.88 Billion | 0.159x | -26.56% |
| 2023-12-31 | NT$11.63 Billion | NT$2.52 Billion | 0.217x | -19.29% |
| 2022-12-31 | NT$11.14 Billion | NT$2.99 Billion | 0.268x | +10.12% |
| 2021-12-31 | NT$10.43 Billion | NT$2.54 Billion | 0.244x | -28.48% |
| 2020-12-31 | NT$7.98 Billion | NT$2.72 Billion | 0.341x | +17.26% |
| 2019-12-31 | NT$7.47 Billion | NT$2.17 Billion | 0.291x | -16.64% |
| 2018-12-31 | NT$6.93 Billion | NT$2.42 Billion | 0.349x | -11.59% |
| 2017-12-31 | NT$6.33 Billion | NT$2.50 Billion | 0.394x | -18.64% |
| 2016-12-31 | NT$5.78 Billion | NT$2.80 Billion | 0.485x | +56.50% |
| 2015-12-31 | NT$4.22 Billion | NT$1.31 Billion | 0.310x | -32.34% |
| 2014-12-31 | NT$3.72 Billion | NT$1.70 Billion | 0.458x | -6.43% |
| 2013-12-31 | NT$3.22 Billion | NT$1.58 Billion | 0.489x | +19.64% |
| 2012-12-31 | NT$2.74 Billion | NT$1.12 Billion | 0.409x | +19.10% |
| 2011-12-31 | NT$2.47 Billion | NT$848.53 Million | 0.343x | +13.46% |
| 2010-12-31 | NT$2.26 Billion | NT$683.89 Million | 0.303x | -12.82% |
| 2009-12-31 | NT$2.08 Billion | NT$720.61 Million | 0.347x | +39.24% |
| 2008-12-31 | NT$1.74 Billion | NT$434.85 Million | 0.249x | +74.65% |
| 2007-12-31 | NT$1.77 Billion | NT$253.11 Million | 0.143x | -48.28% |
| 2006-12-31 | NT$1.70 Billion | NT$468.84 Million | 0.276x | +26.09% |
| 2005-12-31 | NT$1.60 Billion | NT$350.26 Million | 0.219x | +597.83% |
| 2004-12-31 | NT$1.58 Billion | NT$49.53 Million | 0.031x | -65.88% |
| 2003-12-31 | NT$1.48 Billion | NT$136.42 Million | 0.092x | +75.77% |
| 2002-12-31 | NT$1.46 Billion | NT$76.42 Million | 0.052x | -- |